Surrozen Publishes Study In 'eLife' Highlihgitng Potential To Enhance Wnt-Signal Activation In Targeted SWEETS Bispecific Antibodies

6/12/24 8:32:38 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $SRZN alert in real time by email

Targeted protein degradation (TPD*) technologies have demonstrated the potential to produce novel treatment approaches

Surrozen's current SWEETS bispecific antibodies are unique TPD technologies

Results demonstrated that the two new ASGR-targeted SWEETS bispecific antibodies enhanced Wnt-signal activation through the unique TPD platform

Get the next $SRZN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SRZN

Date	Price Target	Rating	Analyst
10/11/2021	$11.00	Buy	B of A Securities
9/15/2021	$20.00	Buy	Guggenheim
9/7/2021	$19.00	Buy	Stifel

More analyst ratings

$SRZN
Press Releases

Fastest customizable press release news feed in the world

Surrozen to Present at Upcoming Healthcare Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Craig Parker, President and Chief Executive Officer, will present at two upcoming healthcare investor conferences. Guggenheim's Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024 Fireside Chat at 3:00 PM ET / 12N PT Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 Presentation at 2:25 PM ET / 11:25 AM PT Interested parties may access the live audio webcast for each conference via the In
11/6/24 4:30:40 PM ET
$SRZN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Surrozen Provides Third Quarter 2024 Financial Results and Business Update
Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected in the first half of 2025 Nominated novel portfolio of preclinical ophthalmology product candidates to R&D pipeline Received $10 million milestone payment from Boehringer Ingelheim strategic collaboration on SZN-413 in retinal vascular associated diseases SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided third quarter 2024 financial result
11/6/24 9:00:09 AM ET
$SRZN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced a strategic research collaboration with privately-held TCGFB, Inc. ("TCGFB") to discover antibody therapeutics targeting Transforming Growth Factor Beta (TGF-β) for the potential treatment of patients with idiopathic pulmonary fibrosis (IPF). Under the terms of the agreement, Surrozen will provide antibody discovery services for a period of up to two years. TCGFB will own all TGF-β product related intellectual property. In exchange
11/4/24 8:30:55 AM ET
$SRZN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Surrozen Publishes Study In 'eLife' Highlihgitng Potential To Enhance Wnt-Signal Activation In Targeted SWEETS Bispecific Antibodies

Chat with this insight

Recent Analyst Ratings for $SRZN

$SRZN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

B of A Securities initiated coverage on Surrozen with a new price target

Guggenheim initiated coverage on Surrozen with a new price target

Stifel initiated coverage on Surrozen with a new price target

$SRZN Leadership Updates

Live Leadership Updates

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

$SRZN Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

$SRZN Financials

Live finance-specific insights

$SRZN SEC Filings

$SRZN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$SRZN Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

SEC Form SCHEDULE 13G filed by Surrozen Inc.

SEC Form SCHEDULE 13G filed by Surrozen Inc.

SEC Form 10-Q filed by Surrozen Inc.

Exec. Vice President, Research Li Yang was granted 400 shares, increasing direct ownership by 4% to 10,888 units (SEC Form 4)

CFO and COO Williams Charles O was granted 400 shares, increasing direct ownership by 7% to 5,863 units (SEC Form 4)

Chief Executive Officer Parker Craig C was granted 400 shares, increasing direct ownership by 7% to 5,824 units (SEC Form 4)

Column Group Iii Gp, Lp bought $2,999,994 worth of shares (193,548 units at $15.50) (SEC Form 4) (Amendment)

Kutzkey Tim bought $2,999,994 worth of shares (193,548 units at $15.50) (SEC Form 4) (Amendment)

Williams Charles O bought 1,474 shares (SEC Form 4)

$SRZN Press Releases

Fastest customizable press release news feed in the world

Surrozen to Present at Upcoming Healthcare Investor Conferences

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

$SRZN Market Insights

Live Market Insights

Surrozen Publishes Study In 'eLife' Highlihgitng Potential To Enhance Wnt-Signal Activation In Targeted SWEETS Bispecific Antibodies

Surrozen Presents Preliminary Results Of Phase 1a Study Of SZN-043 In Liver Cirrhosis Patients At EASL 2024

Surrozen Announces First Patient Dosed In Phase 1b Trial Of SZN-043 For Severe Alcohol-Associated Hepatitis

Recent Analyst Ratings for
$SRZN

$SRZN
Analyst Ratings

$SRZN
Leadership Updates

$SRZN
Large Ownership Changes

$SRZN
Financials

$SRZN
SEC Filings

$SRZN
Insider Trading

$SRZN
Insider Purchases

$SRZN
Press Releases

$SRZN
Market Insights